According to Zhitong Finance App News, Yaojie Ankang-B (02617.HK) announced that the company's core product, tenengotinib (Tinengotinib, TT-00420) combined with novel endocrine therapy (NHT), is used in the Chinese phase II clinical trial of metastatic castration-resistant prostate cancer (mCRPC) that progresses after treatment, and recently completed the first patient administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.